192 related articles for article (PubMed ID: 2887641)
1. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Wiernik PH; Schwartz EL; Einzig A; Strauman JJ; Lipton RB; Dutcher JP
J Clin Oncol; 1987 Aug; 5(8):1232-9. PubMed ID: 2887641
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of taxol given by a 6-hour intravenous infusion.
Brown T; Havlin K; Weiss G; Cagnola J; Koeller J; Kuhn J; Rizzo J; Craig J; Phillips J; Von Hoff D
J Clin Oncol; 1991 Jul; 9(7):1261-7. PubMed ID: 1675263
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of taxol given as a 3-hour infusion every 21 days.
Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW
Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of taxol in patients with malignant melanoma.
Einzig AI; Hochster H; Wiernik PH; Trump DL; Dutcher JP; Garowski E; Sasloff J; Smith TJ
Invest New Drugs; 1991 Feb; 9(1):59-64. PubMed ID: 1673965
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of taxol.
Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of taxol in metastatic melanoma.
Legha SS; Ring S; Papadopoulos N; Raber M; Benjamin RS
Cancer; 1990 Jun; 65(11):2478-81. PubMed ID: 1970948
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.
Murphy WK; Fossella FV; Winn RJ; Shin DM; Hynes HE; Gross HM; Davilla E; Leimert J; Dhingra H; Raber MN
J Natl Cancer Inst; 1993 Mar; 85(5):384-8. PubMed ID: 8094466
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Holmes FA; Walters RS; Theriault RL; Forman AD; Newton LK; Raber MN; Buzdar AU; Frye DK; Hortobagyi GN
J Natl Cancer Inst; 1991 Dec; 83(24):1797-805. PubMed ID: 1683908
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC
Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
Grem JL; Tutsch KD; Simon KJ; Alberti DB; Willson JK; Tormey DC; Swaminathan S; Trump DL
Cancer Treat Rep; 1987 Dec; 71(12):1179-84. PubMed ID: 2891442
[TBL] [Abstract][Full Text] [Related]
12. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity reactions from taxol.
Weiss RB; Donehower RC; Wiernik PH; Ohnuma T; Gralla RJ; Trump DL; Baker JR; Van Echo DA; Von Hoff DD; Leyland-Jones B
J Clin Oncol; 1990 Jul; 8(7):1263-8. PubMed ID: 1972736
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of taxol in patients with advanced cancer.
Donehower RC; Rowinsky EK; Grochow LB; Longnecker SM; Ettinger DS
Cancer Treat Rep; 1987 Dec; 71(12):1171-7. PubMed ID: 2891441
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Shepherd FA; Latreille J; Paul K; Eisenhauer E
Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
[TBL] [Abstract][Full Text] [Related]
16. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Löffler TM; Freund W; Lipke J; Hausamen TU
Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
[TBL] [Abstract][Full Text] [Related]
17. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
19. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
McGuire WP; Rowinsky EK; Rosenshein NB; Grumbine FC; Ettinger DS; Armstrong DK; Donehower RC
Ann Intern Med; 1989 Aug; 111(4):273-9. PubMed ID: 2569287
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Hainsworth JD; Greco FA
Cancer; 1994 Aug; 74(4):1377-82. PubMed ID: 7914470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
